Ruxolitinib treatment of a patient with steroid-dependent severe autoimmunity due to STAT1 gain-of-function mutation

Area of Science:

• Immunology
• Genetics
• Pharmacology

Background:

• Signal transducer and activator of transcription 1 gain-of-function (STAT1 GOF) mutations are a primary cause of chronic mucocutaneous candidiasis (CMC).
• STAT1 GOF mutations frequently present with autoimmune manifestations, complicating patient management.
• This case involves a 3-year-old male with a STAT1 GOF T385M mutation causing steroid-dependent severe autoimmunity and CMC.

Observation:

• The patient received oral ruxolitinib, a Janus kinase (JAK) inhibitor, to manage his severe autoimmune symptoms.
• Immune parameters including interleukin-17A (IL-17A) and interferon-gamma (IFN-γ) levels, and STAT1 phosphorylation were monitored.
• Clinical status, including infection susceptibility and autoimmune activity, was assessed before and during ruxolitinib therapy.

Findings:

• Ruxolitinib treatment led to a decrease in IFN-γ levels and STAT1 phosphorylation, indicating modulation of the JAK-STAT pathway.
• While IL-17A levels did not increase, the patient experienced clinical improvement in autoimmune symptoms.
• Cytomegalovirus reactivation occurred but was successfully managed; no other adverse effects were reported.

Implications:

• JAK1/2 inhibition with ruxolitinib presents a potential therapeutic strategy for both CMC and steroid-dependent autoimmunity in STAT1 GOF patients.
• Sustained clinical benefits may require long-term ruxolitinib administration, as effects diminish upon discontinuation.
• This study highlights the complex interplay between STAT1 GOF mutations, immune dysregulation, and the potential of targeted therapies.